Centessa Pharmaceuticals (STU:260) Long-Term Capital Lease Obligation : €8.04 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Long-Term Capital Lease Obligation?

Centessa Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €8.04 Mil.

Centessa Pharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€8.45 Mil) to Dec. 2023 (€8.15 Mil) and declined from Dec. 2023 (€8.15 Mil) to Mar. 2024 (€8.04 Mil).

Centessa Pharmaceuticals's annual Long-Term Capital Lease Obligation stayed the same from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€8.15 Mil).

Centessa Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Centessa Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Long-Term Capital Lease Obligation Chart

Centessa Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

8.15

Centessa Pharmaceuticals Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial										8.70	8.44	8.45	8.15	8.04

Centessa Pharmaceuticals (STU:260) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Centessa Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Centessa Pharmaceuticals (STU:260) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CNTA:USA

Address

1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT

Website

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals (STU:260) Headlines

No Headlines